We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

153 hedge funds and large institutions have $1.25B invested in Revance Therapeutics, Inc. in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 64 increasing their positions, 38 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 13

68% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 38

6% more funds holding

Funds holding: 144 → 153 (+9)

1% more capital invested

Capital invested by funds: $1.23B → $1.25B (+$11.8M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

35% less call options, than puts

Call options by funds: $6.79M | Put options by funds: $10.5M

Holders
153
Holders Change
+9
Holders Change %
+6.25%
% of All Funds
3.09%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
22
Increased
64
Reduced
38
Closed
13
Calls
$6.79M
Puts
$10.5M
Net Calls
-$3.72M
Net Calls Change
-$8.08M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$11.6M
2
PAI
Palo Alto Investors
California
+$7.62M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$6.76M
4
Citadel Advisors
Citadel Advisors
Florida
+$6.38M
5
Wells Fargo
Wells Fargo
California
+$4.57M

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$23.3M
2
ACH
ArrowMark Colorado Holdings
Colorado
-$21.4M
3
NCM
NovaQuest Capital Management
North Carolina
-$10M
4
FI
Fosun International
China
-$5.51M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$5.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$7.88M +$890K +33,933 +12%
PPA
27
Parametric Portfolio Associates
Washington
$7.45M +$1.12M +42,801 +17%
Citadel Advisors
28
Citadel Advisors
Florida
$6.5M +$6.38M +243,335 +1,586%
Wells Fargo
29
Wells Fargo
California
$6.33M +$4.57M +174,266 +224%
FI
30
Fosun International
China
$5.88M -$5.51M -210,000 -47%
RPAM
31
Rhenman & Partners Asset Management
Sweden
$5.53M – – –
NCM
32
NovaQuest Capital Management
North Carolina
$5.43M -$10M -382,947 -64%
OCM
33
Osterweis Capital Management
California
$4.92M -$876K -33,405 -15%
California Public Employees Retirement System
34
California Public Employees Retirement System
California
$3.62M +$442K +16,853 +13%
Ameriprise
35
Ameriprise
Minnesota
$3.33M -$397K -15,128 -10%
Swiss National Bank
36
Swiss National Bank
Switzerland
$2.92M +$49.8K +1,900 +2%
SEI Investments
37
SEI Investments
Pennsylvania
$2.74M +$73.9K +2,817 +3%
Arrowstreet Capital
38
Arrowstreet Capital
Massachusetts
$2.72M +$2.84M +108,195 New
State of Wisconsin Investment Board
39
State of Wisconsin Investment Board
Wisconsin
$2.61M +$265K +10,100 +11%
EIM
40
Essex Investment Management
Massachusetts
$2.51M +$863K +32,898 +49%
HighTower Advisors
41
HighTower Advisors
Illinois
$2.44M +$1.25M +47,734 +97%
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$2.39M +$252K +9,610 +11%
Morgan Stanley
43
Morgan Stanley
New York
$2.23M -$272K -10,371 -10%
Bank of America
44
Bank of America
North Carolina
$2.23M +$828K +31,580 +55%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$2.21M -$374K -14,252 -14%
TCM
46
Tekla Capital Management
Massachusetts
$2.16M – – –
ECM
47
ExodusPoint Capital Management
New York
$2.15M +$951K +36,263 +73%
State of New Jersey Common Pension Fund D
48
State of New Jersey Common Pension Fund D
New Jersey
$2.04M -$344K -13,104 -14%
MAM
49
Martingale Asset Management
Massachusetts
$1.88M -$1.32M -50,498 -40%
Two Sigma Advisers
50
Two Sigma Advisers
New York
$1.62M +$89.1K +3,400 +6%
1
2
3 4 5

RVNC Hedge Fund Activity: Q3 2020 in Review

153 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2020, worth a combined $1.25B — up 0.96% from $1.23B a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new RVNC positions and 13 closed out — a net gain of 9 holders — while 64 added to existing stakes and 38 trimmed.

The largest buyer was BlackRock, adding an estimated $11.6M. The largest seller was Franklin Resources, cutting an estimated $23.3M.

  • 153 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2020, up from 144 in Q2 2020.
  • Funds reported $1.25B of Revance Therapeutics, Inc. stock for Q3 2020, up 0.96% quarter-over-quarter.
  • 22 funds opened new Revance Therapeutics, Inc. positions in Q3 2020 and 13 closed out, a net change of +9 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q3 2020 was BlackRock, an estimated $11.6M added.
  • The largest Revance Therapeutics, Inc. seller in Q3 2020 was Franklin Resources, an estimated $23.3M sold.

Based on aggregated 13F filings for Q3 2020.